The artificial intelligence (AI) in drug discovery market focuses on the use of advanced technologies like machine learning and data analytics to accelerate and enhance the drug development process. AI helps researchers identify potential drug candidates, predict outcomes, and streamline clinical trials, significantly reducing time and cost compared to traditional methods. This market is growing rapidly due to increasing R&D investments, rising demand for faster drug approvals, and technological advancements in healthcare. North America leads the market due to strong infrastructure and early adoption, while regions like Asia-Pacific are emerging as key growth areas.
According to Fortune Business Insights, the global artificial intelligence (AI) in drug discovery market was valued at USD 3.00 billion in 2022 and is projected to grow from USD 3.54 billion in 2023 to USD 7.94 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.2% during the forecast period (2023–2030). In 2022, North America led the market with a dominant share of 69.33%.
In November 2022, Cyclica secured a USD 1.8 million grant from the Bill & Melinda Gates Foundation to apply its AI‑enabled drug discovery platform toward novel, non‑hormonal compounds targeting multiple low‑data biological targets using its signature approach.